References
- Atkinson A, Kenny JR, Grime K. (2005). Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography–tandem mass spectrometry analysis. Drug Metab Dispos 33:1637–47.
- Berry LM, Zhao Z. (2008). An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2:51–9.
- Burt HJ, Galetin A, Houston JB. (2010). IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. Xenobiotica 40:331–43.
- Galetin A, Gertz M, Houston JB. (2008). Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions. Expert Opin Drug Metab Toxicol 4:909–22.
- Gertz M, Davis JD, Harrison A, et al. (2007). Grapefruit juice–drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 9:785–95.
- Grimm SW, Einolf HJ, Hall SD, et al. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355–70.
- Krayenbuhl JC, Vozeh S, Kondo-Oestreicher M, Dayer P. (1999). Drug–drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 55:559–65.
- Maurer TS, Tabrizi-Fard MA, Fung HL. (2000). Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery. J Pharm Sci 89:1404–14.
- Mayhew BS, Jones DR, Hall SD. (2000). An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031–7.
- Mori K, Hashimoto H, Takatsu H, et al. (2009). Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica 39:415–22.
- Mullins ME, Horowitz BZ, Linden DH, et al. (1998). Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 280:157–8.
- Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 35:246–55.
- Parkinson AP, Kazmi F, Buckley DB, et al. (2011). An evaulation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes. Drug Metab Dispos 39:1370–87.
- Stresser DM, Mao J, Kenny JR, et al. (2014). Exploring concepts of in vitro time-dependent CYP inhibition assays. Expert Opin Drug Metab Toxicol 10:157–74.
- Turner DB, Rostami-Hodjegan A, Tucker GT, Yeo KR. (2007). Prediction of nonspecific hepatic microsomal binding from readily available physiochemical properties. Drug Metab Rev 38:162
- Venkatakrishnan K, Obach RS. (2007). Drug–drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 8:449–62.
- Watanabe A, Nakamura K, Okudaira N, et al. (2007). Risk assessment for drug–drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos 35:1232–8.
- Zhou S, Chan E, Li X, Huang M. (2005). Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 1:3–13.
- Zhou SF, Xue CC, Yu XQ, et al. (2007). Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687–710.
- Zimmerlin A, Trunzer M, Faller B. (2011). CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos 39:1039–46.